PART I . Company Overview We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the potential to address multiple indications. We are developing our product candidates for multiple im...
Q2 FY2026 — expected 2026-09-23
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001193125-26-092546 | EDGAR | 99K words |
| 2025-03-25 | 2024-12-31 | 0000950170-25-044350 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038023 | EDGAR | — |
| 2023-03-06 | 2022-12-31 | 0000950170-23-006279 | EDGAR | — |
| 2022-03-07 | 2021-12-31 | 0000950170-22-002998 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-268086 | EDGAR | 69K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-106916 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-070902 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125294 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-096626 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-059995 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063675 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041303 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021186 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024611 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017181 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0000950170-22-009931 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001193125-26-142114 | EDGAR | 1K words |
| 2026-03-05 | 0001193125-26-092520 | EDGAR | — |
| 2026-01-08 | 0001193125-26-006994 | EDGAR | — |
| 2025-12-31 | 0001193125-25-338318 | EDGAR | — |
| 2025-12-11 | 0001193125-25-315108 | EDGAR | — |
| 2025-11-06 | 0001193125-25-268075 | EDGAR | — |
| 2025-10-17 | 0001193125-25-241951 | EDGAR | — |
| 2025-10-01 | 0001193125-25-227025 | EDGAR | — |
| 2025-09-29 | 0001193125-25-221756 | EDGAR | — |
| 2025-08-12 | 0000950170-25-106913 | EDGAR | — |
83 total filings indexed. 56 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001768446 |
| Ticker | CLYM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.climbbio.com |
| Listed | 2021-08-10 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report